Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
27 Oct, 2022 (Thursday)

            
LIVZON PHARMA(1513)
Analysis:
LIVZON Pharmaceutical Group (1513) is primarily engaged in the R&D, production and sale of pharmaceutical products, which cover drug preparation products, active pharmaceutical ingredients (“APIs”) and intermediates, as well as diagnostic reagents and equipment, covering a wide range of treatment fields such as assisted reproduction, gastroenterology, psychiatry and tumor immunology, and has formed a relatively complete product portfolio. The Group will continue to focus on innovative drugs with outstanding clinical value and high-barrier complex drug preparation. Under the policy of the consistency evaluation and minimum procurement commitment, the Group enjoys unique advantage in terms of APIs and will continue to increase its efforts to integrate API and drug preparation products. For the three months ended 30 September, the Group recorded operating income of RMB3.185 billion, representing an increase of 1.27% as compared to the same period last year. Net profit attributable to the shareholders of the Company was RMB489 million, representing an increase of 25.37%. (I do not hold the above stock)
Strategy:
Buy-in Price: $21.20, Target Price: $23.10, Cut Loss Price: $20.00


SINO BIOPHARM(1177)
Analysis:
Sino Biopharmaceutical Limited (01177) announces that the category I innovative medicine “TDI01”has been approved by the National Medical Products Administration of China on September 2022 to commence clinical trial for the treatment of Novel Coronavirus Pneumonia a (“COVID-19”). TDI01 works by inhibiting viral attack and replication through highly selective inhibition of ROCK2 target to achieve anti-viral effects, which is a novel anti-viral mechanism that has shown significant inhibition of novel coronavirus in vitro and in vivo animal experiments, as well as anti-inflammatory and anti-fibrotic effects. TDI01 is a category I small molecule oral medicine for the treatment of COVID-19 with novel mechanism and brand-new target and structure, which differentiates itself from the traditional anti-novel coronavirus medicines currently under development worldwide and in China. TDI01 is the world`s first innovative small molecule medicine that inhibits novel coronavirus infection to host cells by highly selective inhibition of ROCK2 kinase, thereby achieving significant anti-viral effect. TDI01 has now completed the Phase I clinical trial in the United States and has also completed the human race bridging study of Phase I clinical trial in China. Previously, TDI01 was approved for clinical trials in China and the United States for the treatment of idiopathic pulmonary fibrosis and in China for the treatment of pneumoconiosis. The approval of TDI01 for clinical trials in three major indications in the respiratory field will further increase the Group`s product pipeline of innovative drugs in the respiratory field and bring new treatment option to patients with respiratory diseases.
Strategy:
Buy-in Price: $4.20, Target Price: $4.60, Cut Loss Price: $3.89



CAERI (601965.CH) - Continued to Benefit from the Rising Proportion of High Value-added Business

Company profile

CAERI is the only listed company in the A-share automotive industry that is engaged in automotive technology service business. It has strong automotive R&D and testing capabilities. The businesses involved can be divided into automotive technology service business and industrialized manufacturing business. Among them, the technical service business includes automobile research and development and consultation, and automobile testing and evaluation. The industrialized manufacturing business includes three parts: special vehicles, key parts of rail transit, automobile gas system and its key parts.

Investment Summary

The Improvement of Sales Structure Drives the Growth of Results in H1

In H1 of 2022, CAERI reported a revenue of RMB1,340 million, down 25.58% yoy. The decline in revenue was mainly due to the Company's initiative to control the scale of the equipment manufacturing business with declining market prosperity, resulting in a sharp decline in its revenue by nearly 80% yoy. However, the significant improvement of the sales structure led to a sharp increase in the gross margin during the reporting period, which greatly improved the profitability. The Company reported a net profit attributable to the parent company of RMB300 million, up 14.1% yoy, and a net profit attributable to the parent company excluding non-recurring items of RMB299 million, up 19.26% yoy.

On a closer look at the business segments, 1) the Company reported a revenue of RMB1,139 million in the automotive technical service business, up 30.16% yoy, mainly due to the effectiveness of the Company's strategy of strengthening market development, as well as the continuous optimization of the business structure, which led to a year-on-year improvement in the non-regulatory business such as wind tunnel, new energy and intelligent connected business; 2) the Company reported a revenue of RMB201 million in the equipment manufacturing business, down 78.27% yoy, mainly because under the impact of the market quotation on the SPV modification and sales business, the Company strengthened risk management and controlled the scale of the business, resulting in a year-on-year decrease in the revenue.

Higher Proportion of the Business with High Gross Margin Facilitates a Strong Improvement in the Gross Margin

With the entry of Internet companies and new car-making forces, the vehicle architecture has evolved to "intelligent cockpit + autonomous driving + skateboard chassis", and the integration of automotive technology and cross-sector technology has accelerated. Automobiles have become an important carrier of consumer electronics, and the demand for technical services has further increased. The Company's New Energy Center quickly responded to market changes, and seized the development opportunities of domestic new energy and intelligent connected business. By taking the EIC system and vehicle R&D as the lever, the effect of market development was obvious: During the reporting period, the Company continued to make breakthrough in the innovative business, and the revenue proportion of the automotive technical service business with high gross margin (gross margin of 51%) expanded by 36.4 ppts to 85%.

Meanwhile, the revenue proportion of the equipment manufacturing business with low gross margin decreased to 15%. Specifically, due to the decline in the infrastructure demand, the revenue proportion of SPV modification and sales business, which had a gross margin of only about 4.5%, shrank sharply by 36 ppts to 7.7%. A better sales structure has driven a sharp increase in the profitability: In H1, the Company's comprehensive gross margin reached 43.68%, up 14.69 ppts yoy, and the net profit margin climbed to 23.4%, up 8.3 ppts yoy.

Meanwhile, due to the rising employee compensation, the Company continued to increase the R&D investment in key and core technologies. The selling expense ratio, administration expense ratio and R&D expense ratio saw a year-on-year increase of 1.06 ppts, 2.22 ppts and 1.49 ppts, respectively, driving a year-on-year increase of 4.62 ppts in the period expense ratio.

Continued to Benefit from the Rising Proportion of High Value-added Business

On July 27, the Company's Board of Directors reviewed and approved the East China Headquarters Base construction project, which plans to invest RMB2,349 million to build a new energy vehicle testing and R&D laboratory, an electronic communication and software testing and R&D laboratory, a parts, military supplies and match goods testing and R&D laboratory, and an automotive performance testing and R&D laboratory in Suzhou, Jiangsu Province, and plans to invest RMB33 million to build a hydrogen vehicle testing and R&D laboratory in Changzhou, Jiangsu Province. The completion of the new project will further improve the Company's national strategic layout of the technical service business and comprehensively enhance its technical service capabilities in East China. In the future perspective of the overall slow development and the existing competition in the automotive industry, and the rapid development of new energy vehicles and intelligent applications, automakers will accelerate the launch of new vehicles with more intelligent connected competitiveness. In terms of the policies, the release and implementation of the Medium and Long-term Plan for the Development of Hydrogen Energy Industry (2021-2035), and the Regulations on the Administration of Intelligent Connected Vehicles in the Shenzhen Special Economic Zone will accelerate the development of the domestic automotive industry towards a trend of new energy and intelligence. The Company's high value-added business is expected to enter the fast lane, and its future results will also benefit from the rising proportion of high value-added business.

Investment Thesis

CAERIs state-owned enterprises reform has been continuously advanced. After the launch of the share incentive plan, the incentive mechanism and the degree of marketisation will be significantly improved, such as the forward-looking layout of the intelligent networked electric vehicles.

Considering the high monopoly barrier of the counter-cyclical automotive technology service business of the company, as well as the turning point of result brought by the operation of the new capacity, we give target price of RMB 21.6 yuan, respectively 27/23/20x P/E of our expected EPS for 2022/2023/2024 and an "Accumulate" rating. (Closing price as at 25 October)

Financials

Click Here for PDF format...




Recommendation on 27-10-2022
RecommendationAccumulate
Price on Recommendation Date$ 18.190
Suggested purchase priceN/A
Target Price$ 21.600
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2022 Phillip Securities (HK) Ltd. All Rights Reserved.